Virax
  • Home
  • Trial Info
  • Corporate
  • Announcements
  • Recent Press Articles
  • Investor Information
  • Virax's Technology
    • Immunotherapy
    • Co-X-Gene(TM) Technology
    • FPV Delivery Technology
    • Scientific Published Papers
  • Development Products
  • CEO Interview
  • Alpha Securities Report
Home / Virax's Technology / Scientific Published Papers

Scientific Published Papers

 

Click on the links below to download the articles

 

Published Papers

Influence of IFNγ Co-Expression on the Safety and Antiviral Efficacy of Recombinant Fowlpox Virus HIV Therapeutic Vaccines Following
Interruption of Antiretroviral Therapy, Human Vaccines, Nov/Dec 2008

 

Randomised, Placebo-Controlled, Phase I/IIa Evaluation of the Safety and Immunogenicity of Fowlpox Virus Expressing HIV gag-pol and Interferon-g in HIV-1 Infected Subjects, Human Vaccines, Nov/Dec 2005

 

A recombinant avipoxvirus HIV-1 vaccine expressing interferon-gamma is safe and immunogenic in macaques, Vaccine, 2000

 

Scientific Presentations

Vaccine-induced IgG2 antibodies to HIV antigens are associated with partial control of HIV replication, International AIDS Society, July 2009

 

Randomised, placebo-controlled, phase I/IIa evaluation of the safety, immunogenicity and antiretrovirological properties of an avipox virus vaccine expressing HIV gag-poland interferon-γin HIV-1 infected subjects,  CROI, February 2004

 

Other Scientific Announcements

European Union Patent Grant - 19 September 2007

United States Patent Allowance - 10 July 2007

United States Food & Drug Administration IND Approval - 17 November 2006

CROI - VIR201 & NCHECR Media Release - 12 February 2004

VIR201 Extension Study Results - 16 October 2003

 

*Printer-friendly version

© Copyright Virax 2008. All rights reserved. Site index Legal Contact Us

DDSN Interactive Website Design Melbourne Australia, Web Hosting, Web Development by DDSN InteractiveVirax is built and powered by CM3